Impact Factor
4.14
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.72
4,820 total citations
h5-index
74
h5 depth signal
Cited share
69.8%
748 of 1,071
Total citations
4,820
Citation footprint
Metric signal
4.90
External metric anchor
Self-citation
2.0%
95 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
4,062
Canada
454
China
403
Italy
287
United Kingdom
285
Citing Fields of Research
Oncology
2,730
Breast Cancer
964
Palliative Care
788
Hematology
609
Prostate Cancer
421
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
48,801
Articles tracked across the journal lifetime
Indexed publication set
1,071
748 cited publications
Last 12 months
533
44.4 publications/month
Open access share
35.6%
190 OA publications in the last year
Leading citing country
United States
4,062 citing publications
Leading citing field
Oncology
2,730 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v18n10,Oct. 1965-
v18n10,Oct. 1965-
Active Coverage
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Hematology
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphomas
Issuing & Sponsoring Bodies
Contributor
American Cancer Society
Contributor
American Society of Clinical Oncology
Contributor
American Society of Therapeutic Radiologists
Contributor
James Ewing Society
Broad Categories
Neoplasms
Palliative Care
Hematology
Breast Cancer
Prostate Cancer
Lung Cancer
Musculoskeletal & Nerve Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/cncr.70590
Open DOI
Patients gain potential options for treatment of advanced NSCLC
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, trials show that ivonescimab combined with chemotherapy improved overall survival, and sunvozertinib improve...
02
03
DOI 10.1002/cncr.70591
Open DOI
Adjuvant selpercatinib improved EFS in early‐stage RET ‐positive NSCLC
04
DOI 10.1002/cncr.70646
Open DOI
Real‐world outcomes in circulating tumor DNA–detected isocitrate dehydrogenase 1–mutant cholangiocarcinoma: First‐line gemcitabine and cisplatin with versus without immunotherapy
Background: Comprehensive genomic profiling (CGP) is recommended for advanced cholangiocarcinoma (aCCA). Circulating tumor DNA (ctDNA) testing provides a noninvasive alternative with concordance to tissue. Standard first‐line (1L) therap...
05
DOI 10.1002/cncr.70635
Open DOI
Cancer risks associated with BRCA1 and BRCA2 : Overview and management
The BRCA1 and BRCA2 tumor suppressor genes are integral to the repair of DNA double‐strand breaks. Therefore, germline pathogenic variants (PVs) in either of these genes are associated with an increased risk of developing hereditary canc...
06
DOI 10.1002/cncr.70649
Open DOI
Blood‐based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG‐GY012
Background: The NRG‐GY012 phase 2 trial evaluated olaparib, cediranib, and the combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer (EC). Predictive and prognostic associations between blood‐based biom...
07
DOI 10.1002/cncr.70644
Open DOI
Evaluation of early C‐reactive protein kinetics as an early response marker in biliary tract cancer treated with combined chemoimmunotherapy: A multicenter observational study
Background: Reliable prognostic biomarkers for treatment response in patients with biliary tract cancer (BTC) who receive chemoimmunotherapy are still lacking. The objective of this study was to evaluate the potential of early C‐reactive...
08
DOI 10.1002/cncr.70622
Open DOI
Evolving role of proton therapy in contemporary oncology
Proton therapy offers a distinct physical advantage over photon radiotherapy through the Bragg peak dose concentration in target with both lower integral dose and finite path length, and sharper penumbra as compared to photons, collectiv...
09
DOI 10.1002/cncr.70645
Open DOI
Increased risk of stroke after a new cancer diagnosis—Where are the knowledge gaps currently?
A retrospective, population‐based study from Israel using linked cancer and stroke registries quantified the excess risk in cancer patients by cancer site, stage, and age, expresses in both absolute and relative measures. This study furt...
10
DOI 10.1002/cncr.70594
Open DOI
Delays in breast cancer presentation, diagnosis, and treatment in young women
Background: Breast cancer (BC) in young patients is often identified at later stages, which can result in poor prognosis. It is important to investigate the factors influencing care delays and how delays affect outcomes. Methods: This st...
Bibliographical & Catalog Notes
The supplement on the American Cancer Society Second National Conference on Cancer Genetics, San Francisco, California, June 26-28, 1998, included with Vol. 86, no. 11 (Dec. 1, 1999) replaces the version included with Vol. 86, no. 8 (Oct. 15, 1999). Supplement was republished due to a pagination error in the Oct. 1999 version.
Supplements accompany some numbers.
Also issued online.
Microfilm. v. 26 (1970 Jul-Sept). 1 microfilm reel : negative ; 35 mm.
Journal of the American Cancer Society and official journal of the James Ewing Society; also, 1970- of the American Society of Clinical Oncology, and July 1972- of the American Society of Therapeutic Radiologists (contains proceedings of their meetings).
Indexes: Vols. 18-34, 1965-74. 1 v.
From 1997-2009, every 3rd volume per year had section title: Cytopathology. Beginning with v.118 (2010), Cancer cytopathology issued independently.
Vol. 72, no. 6 (SEP 15 1993)19960325 Notice published Printed on acid-free paper